3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
3
Head & Neck
2
Gynecologic
2
Thoracic
1
Sarcoma
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Conditions
Sarcoma
43
Melanoma
19
Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
11
Neoplasm Metastasis
11
Carcinoma, Non-Small-Cell Lung
9
Breast Neoplasms
9
Glioblastoma
8
Colorectal Neoplasms
8
Triple Negative Breast Neoplasms
7
Pancreatic Neoplasms
7
Ovarian Neoplasms
7
Gliosarcoma
7
Lung Neoplasms
6
Histiocytoma, Malignant Fibrous
6
Carcinoma, Renal Cell
6
Osteosarcoma
5
Liposarcoma
5
Head and Neck Neoplasms
5
Carcinoma, Hepatocellular
5
Uterine Cervical Neoplasms
4
Sarcoma, Synovial
4
Sarcoma, Kaposi
4
Neurofibrosarcoma
4
Lymphoma
4
Hemangiosarcoma
4
Carcinoma, Merkel Cell
4
Urinary Bladder Neoplasms
3
Stomach Neoplasms
3
Recurrence
3
Interventions
Temozolomide
58
Radiotherapy
50
Carmustine
23
Carboplatin
18
Filgrastim
17
Chemotherapy, Adjuvant
17
Irinotecan
12
Surgical Procedures, Operative
11
Peripheral Blood Stem Cell Transplantation
11
O(6)-benzylguanine
10
Magnetic Resonance Spectroscopy
10
Drug Therapy
10
Etoposide
9
sargramostim
8
Thiotepa
8
Thalidomide
8
Cyclophosphamide
8
Bevacizumab
8
Procarbazine
7
Gene Expression Profiling
7
Erlotinib Hydrochloride
7
Radiation
6
Everolimus
6
Cisplatin
6
motexafin gadolinium
5
aldesleukin
5
Topotecan
5
Imatinib Mesylate
5
Celecoxib
5
Busulfan
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Central Nervous System Neoplasms
×
pembrolizumab
×
Sarcoma
×
Clear all
NCT03012620
2024-02-28
AcSé
UNICANCER
Phase 2
Completed
334 enrolled